LUPIN STOCK CURRENT UPDATE

Q4 FY25 Results: Lupin announced its Q4 FY25 results yesterday, May 14, 2025. The company's net profit more than doubled to ₹772 crore compared to ₹359 crore in the same period last year, exceeding analysts' estimates. Revenue also saw a healthy increase of 14.2% to ₹5,667 crore. The board has recommended a dividend of ₹12 per share. Post-Results Stock Reaction: Following the strong Q4 results, Lupin's share price has shown positive movement today, with an initial surge of over 2% in the morning. US Market Performance: Lupin's growth is significantly driven by its performance in the US market. Recent launches of generic drugs like Tolvaptan (for kidney disease) and gXarelto are expected to boost US sales. Existing products like gSpiriva, gMyrbetriq, gSupreb, and gPrezista are also performing well. Lupin received USFDA approval for generic Tolvaptan. India Market Growth: In India, Lupin's chronic therapy segment is expected to be a key growth driver, focusing on treatments for diabetes, heart disease, and asthma. Investors Meet: Lupin is scheduled to conduct an Investors Meet 2025 in Mumbai today, May 15, 2025, at 5:30 PM IST for analysts and institutional investors. Lupin has a significant presence in various therapeutic areas, including: Cardiovascular Diabetology Asthma Pediatrics Central Nervous System Gastro-intestinal Anti-infectives Nonsteroidal Anti-inflammatory Drugs (NSAIDs)   Anti-TB   Cephalosporins The company has manufacturing facilities across India, the United States, Mexico, and Brazil, with its commercial operations extending to global markets. Lupin also focuses on complex generics and biosimilar products. Key Financial Metrics (as of recent reports): Market Capitalization: Approximately ₹94,608 crore. P/E Ratio: Around 32.97. Dividend Yield: Approximately 0.39%. 52-Week High: ₹2,403.45 (reached on January 2, 2025). 52-Week Low: ₹1,493.75 (reached on June 4, 2024).